The Food and Drug Administration approved two breakthrough-designated oncologics this week, including its fastest novel approval of 2020: Seattle Genetics Inc.’s Tukysa (tucatinib) for HER2-positive breast cancer.
New product submission news was light, headlined by Regeneron Pharmaceuticals Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?